Recent FDA approvals include toripalimab-tpzi (Loqtorzi) for nasopharyngeal carcinoma, mirvetuximab soravtansine-gynx (Elahere) for ovarian cancer, and lifileucel (Amtagvi) as the first TIL therapy for advanced melanoma.
Open the full topic